MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
REPORTVALIDATION,AUTOMATION DN...	RVDNPLB063	40	F	RVDNPLB063
Ordering Phys				**DOB** 01/01/1971
Client Order # RVDNPLB063	**Account Information**			**Report Notes**
Collected 11/18/2011 11:31	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 11/21/2011 11:03				

Test	Flag	Results	Unit	Reference Value	Perform Site*
UGT1A1 Sequence, Irinotecan, Saliva			REPORTED 11/19/2011 13:39		
UGT1A1 Gene Sequence, Irinotecan					
UGT1A1 Irinotecan Result					MCR
A mutation was NOT detected in the UGT1A1 gene.					
Reviewed by		Jamie Bruflat			MCR
UGT1A1 Irinotecan Interp					MCR

Both copies of the UGT1A1 gene have the normal TA6 (*1) promoter repeat, which is consistent with normal activity of the UGT1A1 enzyme and low risk for severe neutropenia with irinotecan administration. Therefore, the genotype observed in this individual decreases the likelihood of UGT1A1 deficiency and irinotecan toxicity. However, it should be noted that irinotecan toxicity cannot be entirely ruled out because of the low possibility that mutations in UGT1A1 or other genes involved in irinotecan metabolism and disposition may be present and undetectable by the methods employed here. The irinotecan package labeling should be consulted for drug dosing recommendations.
Bidirectional DNA sequence analysis was used to test for the presence of mutations in the promoter, exons, exon-intron boundaries, and 3'-untranslated region of the UGT1A1 gene. A small percentage of individuals who manifest toxicity following irinotecan chemotherapy may have a mutation that is not identified by the methods described above. A list of common polymorphisms identified for this patient is available from the laboratory upon request.

CAUTIONS: Rare polymorphisms exist that could lead to false negative or false positive results. Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Large deletions or rearrangements are not detected by this assay and these may affect UGT1A1 protein expression and the ability to conjugate irinotecan metabolites.
Laboratory developed test.

UGT, Full Gene Sequencing		Performed			MCR

* Performing Site:

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

Patient Name	Collection Date and Time	Report Status
REPORTVALIDATION,AUTOMATION DN...	11/18/2011 11:31	Final
Page 1 of 1		** End of Report **

* Report times for Mayo performed tests are CST/CDT